» Authors » Daniel Vallbohmer

Daniel Vallbohmer

Explore the profile of Daniel Vallbohmer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 80
Citations 1365
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Vallbohmer D, Fuchs H, Dittmar R, Krones C
Innov Surg Sci . 2019 Oct; 4(1):3-6. PMID: 31579795
Surgery is indeed one of the most fascinating medical professions. However, it is also a stressful field of work with a high workload, and often leaves little time for personal...
2.
Schumacher S, Bartenhagen C, Hoffmann M, Will D, Fischer J, Baldus S, et al.
Br J Cancer . 2017 Jul; 117(5):725-733. PMID: 28728164
Background: Chromosomal instability (CIN) has repeatedly been identified as a prognostic marker. Here we evaluated the percentage of aberrant genome per cell (PAG) as a measure of CIN in single...
3.
Sisic L, Vallbohmer D, Stoecklein N, Blank S, Schmidt T, Driemel C, et al.
Oncol Lett . 2015 Dec; 10(2):869-874. PMID: 26622585
Despite the implementation of multimodality treatment strategies, the persistently poor prognosis of gastric cancer patients is predominantly caused by the lack of predictive markers for response assessment in the neoadjuvant...
4.
Kraus S, Vay C, Baldus S, Knoefel W, Stoecklein N, Vallbohmer D
Oncol Lett . 2015 Dec; 10(2):863-868. PMID: 26622584
The wingless-type mouse mammary tumor virus integration site family (Wnt) pathway plays a major role in the carcinogenesis of colorectal cancer (CRC). Its most important effector, the nuclear β-catenin, influences...
5.
Odenthal M, Hee J, Gockel I, Sisic L, Schmitz J, Stoecklein N, et al.
Int J Cancer . 2014 Nov; 137(1):230-7. PMID: 25429911
Neoadjuvant multimodality treatment is frequently applied to improve the poor prognosis of locally advanced adenocarcinomas of the gastroesophageal junction. This study aimed to asses if serum microRNA profiles are useable...
6.
Vay C, Hosch S, Stoecklein N, Klein C, Vallbohmer D, Link B, et al.
PLoS One . 2014 Nov; 9(11):e109026. PMID: 25398092
The integrins are a family of heterodimeric transmembrane signaling receptors that mediate the adhesive properties of epithelial cells affecting cell growth and differentiation. In many epithelial malignancies, altered integrin expression...
7.
Al-Shahrabani F, Vallbohmer D, Angenendt S, Knoefel W
World J Clin Oncol . 2014 Oct; 5(4):595-603. PMID: 25302164
Lung cancer represents the leading cause of cancer mortality worldwide. Despite improvements in preoperative staging, surgical techniques, neoadjuvant/adjuvant options and postoperative care, there are still major difficulties in significantly improving...
8.
Vallbohmer D, Sisic L, Blank S, Kraus S, Stoecklein N, Knoefel W, et al.
Oncol Res Treat . 2014 Apr; 37(3):97-104. PMID: 24685912
Background: Multimodality treatment options in locally advanced adenocarcinomas of the esophagogastric junction (AEGs) have been established in the last years. However, the therapeutic approach in patients with clinically staged cT2...
9.
Graf D, Vallbohmer D, Knoefel W, Kropil P, Antoch G, Sagir A, et al.
Eur J Intern Med . 2014 Mar; 25(5):430-7. PMID: 24666568
Hepatocellular carcinoma (HCC) represents the most common liver cancer with an increasing incidence and it accounts for the third most common cause of cancer-related death worldwide. Even though the clinical...
10.
Wijnhoven B, Toxopeus E, Vallbohmer D, Knoefel W, Krasna M, Perez K, et al.
Ann N Y Acad Sci . 2013 Oct; 1300:213-225. PMID: 24117644
This paper presents commentaries on neoadjuvant treatment esophagectomy; the prognostic and predictive effects of single nucleotide polymorphisms (SNP) in the multimodality therapy of esophageal cancer; optimal preoperative treatment prior to...